Lekili M.Muezzinoglu T.Nese N.Temeltas G.2024-07-222024-07-22201017287731http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/18455Targeted therapy in the management of metastatic renal cell cancer has been recently introduced to urology practice. The drugs used for management are used in a very limited number of patients and only for clear cell histology. We present a case where we administered sorafenib, a multikinase inhibitor of tumor-cell proliferation and angiogenesis, to a patient with metastatic renal cell carcinoma of clear cell histology. We found that our results were different from those of previously reported studies, because sarcomatoid differentiation was evident in a histological examination of this case. There was an excellent response to sorafenib. This case report might provide evidence that antiangiogenic agents may be active in any histological type of renal cell carcinoma. However, there are no available data to demonstrate the duration of response and survival benefit. © 2010 Elsevier.EnglishAll Open Access; Bronze Open AccessAdultAntineoplastic AgentsBenzenesulfonatesCarcinoma, Renal CellHumansKidney NeoplasmsMalePyridinesSarcomaalpha interferoninterleukin 2sorafenibadultarticlebrain edemabrain metastasiscancer immunotherapycancer stagingcase reportclear cell carcinomacomputer assisted tomographyhand foot syndromehumankidney carcinomalung metastasismalenephrectomypostoperative caresarcomasurvival timetumor differentiationArticle10.1016/S1726-4901(10)70056-3